Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …

Background Systemic therapies have improved the management of hepatocellular
carcinoma, but there is still a need to further enhance overall survival in first-line advanced …

Programmed cell death protein 1 (PD-1) inhibitors have modest efficacy as a monotherapy
in hepatocellular carcinoma (HCC). A personalized therapeutic cancer vaccine (PTCV) may …

Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

The past decade has witnessed significant advances in the systemic treatment of advanced
hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies …

Importance Hepatocellular carcinoma (HCC) is the sixth most common malignancy and
fourth leading cause of cancer-related death worldwide. Recent advances in systemic and …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …